Luxturna: FDA documents reveal the value of a costly gene therapy
- PMID: 30711576
- DOI: 10.1016/j.drudis.2019.01.019
Luxturna: FDA documents reveal the value of a costly gene therapy
Abstract
In 2017, the US Food and Drug Administration (FDA) approved voretigene neparvovec-rzyl (Luxturna), a gene therapy used to treat a rare form of inherited blindness. Widely described by the media as a curative treatment that 'restores vision', it was priced at US$850000. Although voretigene neparvovec-rzyl represents a substantial therapeutic advance, most reports have failed to adequately describe study outcomes as documented by FDA reviewers. These documents reveal that the drug is not expected to restore normal vision, that only about half of treated patients met the FDA's threshold for minimally meaningful improvement, that improvements might not persist long-term, that the most common measure of visual function was rejected as a primary endpoint after yielding mixed results, and that two patients experienced permanent vision loss. Over US$100 million of additional publicly-funded costs are not evident from the US$850000 figure.
Copyright © 2019 Elsevier Ltd. All rights reserved.
Similar articles
-
Voretigene neparvovec-rzyl (Luxturna) for inherited retinal dystrophy.Med Lett Drugs Ther. 2018 Mar 26;60(1543):53-55. Med Lett Drugs Ther. 2018. PMID: 29635265 No abstract available.
-
Bilateral Subretinal Voretigene Neparvovec-rzyl (Luxturna) Gene Therapy.Ophthalmol Retina. 2019 May;3(5):450. doi: 10.1016/j.oret.2019.02.007. Ophthalmol Retina. 2019. PMID: 31044739 No abstract available.
-
Clinical Perspective: Treating RPE65-Associated Retinal Dystrophy.Mol Ther. 2021 Feb 3;29(2):442-463. doi: 10.1016/j.ymthe.2020.11.029. Epub 2020 Dec 3. Mol Ther. 2021. PMID: 33278565 Free PMC article. Review.
-
Lessons Learned from the Development of the First FDA-Approved Gene Therapy Drug, Voretigene Neparvovec-rzyl.Cold Spring Harb Perspect Med. 2023 May 2;13(5):a041307. doi: 10.1101/cshperspect.a041307. Cold Spring Harb Perspect Med. 2023. PMID: 36167727 Review.
-
Voretigene Neparvovec: A Review in RPE65 Mutation-Associated Inherited Retinal Dystrophy.Mol Diagn Ther. 2020 Aug;24(4):487-495. doi: 10.1007/s40291-020-00475-6. Mol Diagn Ther. 2020. PMID: 32535767 Review.
Cited by
-
Liquid foam improves potency and safety of gene therapy vectors.Nat Commun. 2024 May 28;15(1):4523. doi: 10.1038/s41467-024-48753-9. Nat Commun. 2024. PMID: 38806464 Free PMC article.
-
Intravitreal Delivery of PEGylated-ECO Plasmid DNA Nanoparticles for Gene Therapy of Stargardt Disease.Pharm Res. 2024 Apr;41(4):807-817. doi: 10.1007/s11095-024-03679-1. Epub 2024 Mar 5. Pharm Res. 2024. PMID: 38443629
-
Unlocking therapeutic potential: dual gene therapy for ameliorating the disease phenotypes in a mouse model of RPE65 Leber congenital amaurosis.Front Med (Lausanne). 2024 Jan 9;10:1291795. doi: 10.3389/fmed.2023.1291795. eCollection 2023. Front Med (Lausanne). 2024. PMID: 38264046 Free PMC article.
-
Inhibition of DNA-dependent protein kinase catalytic subunit boosts rAAV transduction of polarized human airway epithelium.Mol Ther Methods Clin Dev. 2023 Sep 21;31:101115. doi: 10.1016/j.omtm.2023.101115. eCollection 2023 Dec 14. Mol Ther Methods Clin Dev. 2023. PMID: 37841417 Free PMC article.
-
Lipid nanoparticles with PEG-variant surface modifications mediate genome editing in the mouse retina.Nat Commun. 2023 Oct 13;14(1):6468. doi: 10.1038/s41467-023-42189-3. Nat Commun. 2023. PMID: 37833442 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous